Latest Content

Toragen CEO Sandra Coufal, MD, discusses why the company is targeting HPV’s overlooked E5 protein, positioning its small-molecule therapy as a potential complement to checkpoint inhibitors like Keytruda across HPV-driven cancers.

Bristol Myers Squibb and Incyte expand AI capabilities through major collaborations aimed at embedding agentic and molecular AI directly into drug discovery, development, and enterprise operations.

Sandra Coufal, MD, CEO of Toragen, says the company is positioning its HPV E5 inhibitor TGN-S15 not as a competitor to Merck’s Keytruda, but as a combination partner designed to enhance checkpoint inhibition.

MedicNova’s chief business officer David Crean explains how well-intentioned but poorly executed programs at FDA are causing tension between the agency and the industry.

Dr. Richard Graham discusses the distinction between real-time data and real-time oversite and how one option may present better results than the other.

In today’s Pharmaceutical Executive Daily, the Trump administration expands TrumpRx to include more than 600 generic medicines, industry leaders rethink pharma’s traditional go-to-market model, and a biotech funding roundup highlights continued investment in early-stage therapeutics and radiopharmaceutical development.

Sandra Coufal, MD, CEO of Toragen, explains how the company’s Scientific Advisory Board was built to provide highly specialized expertise around HPV biology, immuno-oncology, and clinical development as TGN-S15 advances through trials.

The Trump administration has expanded TrumpRx to include more than 600 generic medications and integrated price comparison tools with partners including Amazon Pharmacy, Cost Plus Drugs, and GoodRx, broadening the platform beyond its original focus.

Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven commercialization in reshaping how manufacturers engage patients, physicians and the broader healthcare ecosystem.

Dr. Richard Graham details how real-time data review may reduce timelines but also allow for bad data or outcomes.

Investors seeking predictability are adjusting their strategies in the current regulatory environment.

In today’s Pharmaceutical Executive Daily, the FDA grants breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a wave of leadership departures leaves the FDA facing renewed uncertainty at the top of the agency, and Regeneron enters a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates.

FDA undergoes leadership upheaval, leaving key drug and biologics divisions under interim control and raising concerns over regulatory continuity amid turnover at the agency’s highest levels.